Zacks Investment Research lowered shares of Fibrocell Science (NASDAQ:FCSC) from a buy rating to a hold rating in a research report report published on Wednesday morning.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Separately, HC Wainwright reaffirmed a buy rating and issued a $6.00 target price on shares of Fibrocell Science in a research note on Tuesday, March 6th.

Fibrocell Science (FCSC) opened at $0.58 on Wednesday. The stock has a market cap of $15.07, a PE ratio of -0.32 and a beta of 0.51. Fibrocell Science has a one year low of $0.51 and a one year high of $4.64.

In other Fibrocell Science news, major shareholder Randal J. Kirk bought 2,727,273 shares of Fibrocell Science stock in a transaction dated Monday, December 11th. The shares were bought at an average price of $0.77 per share, with a total value of $2,100,000.21. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Parametric Portfolio Associates LLC boosted its stake in shares of Fibrocell Science by 264.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock valued at $194,000 after purchasing an additional 35,000 shares during the last quarter. FNY Partners Fund LP bought a new position in shares of Fibrocell Science in the 4th quarter valued at about $129,000. Pura Vida Investments LLC bought a new position in shares of Fibrocell Science in the 3rd quarter valued at about $909,000. Anson Funds Management LP bought a new position in shares of Fibrocell Science in the 4th quarter valued at about $287,000. Finally, Armistice Capital LLC bought a new position in shares of Fibrocell Science in the 4th quarter valued at about $393,000. 48.79% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Fibrocell Science (FCSC) Lowered to Hold at Zacks Investment Research” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.